Showing results (111-120 of 128) with videos related to

Sort By:
Pageof 13
The Journal of Clinical Investigation|December 10, 2024
C2230, a preferential use- and state-dependent CaV2.2 channel blocker, mitigates pain behaviors across multiple pain modelsCheng Tang, Kimberly Gomez, Yan Chen, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|December 12, 2017
Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative StudyMohamed A Kharfan-Dabaja, Renju Raj, Liana Nikolaenko, et al.
Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.
Journal for Immunotherapy of Cancer|July 29, 2025
Comparison of axicabtagene ciloleucel and tisagenlecleucel patient CAR-T cell products by single-cell RNA sequencingXiaoqing Yu, Michael D Jain, Meghan A Menges, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 16, 2025
Sarcopenia and Skeletal Muscle Loss after CAR T-cell Therapy in Diffuse Large B cell LymphomaKhushali Jhaveri, Ram Thapa, Dalia Ercan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 16, 2024
Acute Lymphoblastic Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in OncologyBijal Shah, Ryan J Mattison, Ramzi Abboud, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 16, 2019
Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2019Patrick A Brown, Matthew Wieduwilt, Aaron Logan, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 12, 2025
Pediatric Acute Lymphoblastic Leukemia, Version 2.2025, NCCN Clinical Practice Guidelines In OncologyHiroto Inaba, David Teachey, Colleen Annesley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 8, 2023
Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T ConsortiumYucai Wang, Preetesh Jain, Frederick L Locke, et al.
Pageof 13